Merck’s Keytruda plus chemotherapy meets primary endpoint in mTNBC trial

This article was originally published here

Keytruda plus chemotherapy achieved one of its dual primary endpoints of PFS in patients with mTNBC whose tumours expressed PD-L1. Keytruda, an anti-PD-1 therapy, works by blocking the

The post Merck’s Keytruda plus chemotherapy meets primary endpoint in mTNBC trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply